KRAS and colorectal carcinoma: Besides, as another frequently mutant gene in CRC, mutant KRAS leads to resistance to EGFR inhibitors (EGFRIs), cetuximab and panitumumab, in metastatic CRC patients, whereas patients with wild‐type KRAS respond well to EGFRIs (Martinelli et al, 2020).